BILL & MELINDA GATES FOUNDATION

Their core work

The Bill & Melinda Gates Foundation is the world's largest private philanthropic organization, operating at the intersection of global public health and development finance. Within H2020, the Foundation participates as a strategic partner and co-funder in large-scale infectious disease R&D consortia — specifically tuberculosis drug regimen development and COVID-19 treatment acceleration. Their core contribution is not laboratory research but rather global health systems expertise, access to clinical networks in low- and middle-income countries, and the ability to bridge EU research funding with complementary private philanthropic capital. They represent a rare non-European actor in EU research consortia, included precisely because the target diseases disproportionately affect populations outside Europe that no EU institution can reach on its own.

What they specialise in

How they've shifted over time

Both H2020 projects launched simultaneously in 2020, making true temporal evolution within the EU programme impossible to assess from this data alone. The keyword split does reveal a dual-track strategy active in that single year: ERA4TB addressed tuberculosis — a longstanding endemic disease priority for the Foundation — while CARE pivoted immediately to COVID-19 and repurposed drugs as the pandemic emerged in real time. The shift from 'pan-TB regimen, preclinical development' to 'COVID-19, SARS-CoV-2, repurposed drugs' reflects not a change in mission but an expansion to include emergency pandemic response alongside long-horizon chronic infectious disease work.

The Foundation's concurrent engagement in both TB (a disease of persistent poverty) and COVID-19 (an acute pandemic) signals that future EU collaborations will likely target either endemic neglected diseases or rapid-response pandemic preparedness — both framed around affordable, scalable interventions designed for global health equity rather than European markets alone.

How they like to work

The Gates Foundation never leads EU projects — it enters exclusively as a participant, consistent with its role as a strategic co-funder and network enabler rather than a research executor. Despite only two projects, their consortium footprint is unusually wide: 72 unique partners across 15 countries, which implies participation in some of the broadest R&D consortia within H2020. Working with them means accessing a globally connected partner who brings complementary private funding and real-world health implementation networks in endemic-disease regions, but who will not be driving the consortium's day-to-day research agenda.

The Foundation has connected with 72 unique consortium partners across 15 countries through just two projects — an exceptionally wide network for such a small H2020 footprint. Their partnerships span European academic and pharmaceutical institutions alongside clinical networks in endemic-disease regions, reflecting a reach that extends well beyond EU borders.

What sets them apart

The Gates Foundation is the only major US-based private philanthropic foundation regularly entering H2020 consortia, bringing a combination of complementary private funding, global clinical trial infrastructure in low-income countries, and direct influence over the global health policy agenda. No European institution can replicate their access to sub-Saharan African and South Asian health systems — which is precisely why they are included in consortia targeting diseases like tuberculosis. For any consortium working on global health equity, infectious disease, or affordable medicine development, they are a uniquely powerful non-competing partner with resources that amplify rather than dilute EU funding.

Highlights from their portfolio

• ERA4TB
  A flagship 6-year pan-European tuberculosis regimen development programme (2020-2026), ERA4TB is one of the most ambitious TB drug discovery consortia in H2020, targeting a new combination regimen capable of treating all TB forms including drug-resistant strains — a global health priority the Foundation has championed for over a decade.
• CARE
  Launched at the very onset of the COVID-19 pandemic in 2020, CARE focused on rapidly repurposing existing approved drugs for SARS-CoV-2 treatment, a high-speed, cost-conscious approach that directly mirrors the Foundation's mission of delivering affordable interventions for global health crises.